Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Francesca Palandri(Istituto Oncologico Romagnolo), Valerio De Stefano(Agostino Gemelli University Polyclinic), Alessia Tieghi(Azienda Sanitaria Unità Locale di Reggio Emilia), Mario Tiribelli(University of Udine), Mirko Farina(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Alessandra D’Addio(Azienda Unità Sanitaria Locale Della Romagna), Elena Rossi(Università Cattolica del Sacro Cuore), Giuseppe A. Palumbo(University of Catania), Erika Morsia(Marche Polytechnic University), Massimo Breccia(Policlinico Umberto I), Filippo Branzanti(University of Bologna), Elena Maria Elli(Azienda Ospedaliera San Gerardo), Florian H. Heidel(Medizinische Hochschule Hannover), Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Francesco Cavazzini(University of Ferrara), Fabrizio Cavalca(Azienda Ospedaliera San Gerardo), Alessandra Dedola(University of Bologna), Roberto Latagliata(Ospedale di Belcolle)
Cited by 6
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism
|Thrombosis and Haemostasis|2001|235
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin, Protein C, Protein S Deficiency, or Activated Protein C Resistance
|Arteriosclerosis Thrombosis and Vascular Biology|1999|161